Get the Stockscreener App
65.03
0.07%
0.1619
Halozyme Therapeutics Inc stock is traded at $65.03, with a volume of 240.37K.
It is up +0.07% in the last 24 hours and down -5.43% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$65.19
Open:
$65.98
24h Volume:
240.37K
Relative Volume:
0.12
Market Cap:
$7.60B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
21.53
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
-0.93%
1M Performance:
-5.43%
6M Performance:
+6.61%
1Y Performance:
+14.15%
1-Day Range:
$64.97
$66.21
1-Week Range:
$63.84
$66.97
52-Week Range:
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
64.97 | 7.63B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.00 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.70 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.76 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.09 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Torray Investment Partners LLC Has $2.08 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arkadios Wealth Advisors Acquires 11,457 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Will Halozyme Therapeutics Inc. price bounce be sustainableJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
Will Halozyme Therapeutics Inc. stock benefit from upcoming earnings reportsQuarterly Portfolio Review & AI Driven Price Predictions - newser.com
Can Halozyme Therapeutics Inc. stock continue upward trendTrade Volume Summary & Low Volatility Stock Suggestions - newser.com
Using Python tools to backtest Halozyme Therapeutics Inc. strategiesWeekly Trend Recap & Technical Pattern Based Signals - newser.com
Halozyme Therapeutics (HALO) Anticipates Strong Q3 Earnings Grow - GuruFocus
Will Halozyme Therapeutics Inc. stock see PE expansionMarket Activity Report & High Accuracy Investment Signals - newser.com
Why Halozyme Therapeutics Inc. stock could be next big winnerShort Setup & Real-Time Volume Triggers - newser.com
Retirement Systems of Alabama Sells 4,246 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Combining price and volume data for Halozyme Therapeutics Inc.Layoff News & Expert Approved Momentum Trade Ideas - newser.com
AlphaQuest LLC Purchases 5,133 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Will Halozyme Therapeutics Inc. stock benefit from infrastructure spendingCPI Data & Proven Capital Preservation Methods - newser.com
HALOZYME THERAPEUTICS Earnings Preview: Recent $HALO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
What insider trading reveals about Halozyme Therapeutics Inc. stockJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - newser.com
Halozyme Therapeutics, Inc. $HALO Stock Position Lowered by Hantz Financial Services Inc. - MarketBeat
Tools to assess Halozyme Therapeutics Inc.’s risk profilePortfolio Return Summary & Accurate Entry/Exit Alerts - newser.com
Backtesting results for Halozyme Therapeutics Inc. trading strategies2025 Fundamental Recap & AI Driven Stock Reports - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersWeekly Trend Recap & AI Powered Trade Plan Recommendations - newser.com
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients - GlobeNewswire Inc.
Halozyme Therapeutics, Inc. $HALO Shares Acquired by Mizuho Markets Americas LLC - MarketBeat
94,601 Shares in Halozyme Therapeutics, Inc. $HALO Bought by Y Intercept Hong Kong Ltd - MarketBeat
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Sale |
71.20 |
20,000 |
1,424,083 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Sale |
69.03 |
20,000 |
1,380,638 |
733,719 |
| Connaughton Bernadette | Director |
Oct 01 '25 |
Sale |
75.24 |
2,000 |
150,481 |
44,952 |
0.66%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):